AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28197932
Drug: Triptorelin doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin doses (0.2, 0.3, 0.4 mg)
Trial: 23890595
Drug: aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aripiprazole once-monthly 200mg
Trial: 23890595
Drug: aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aripiprazole once-monthly 300mg
Trial: 23890595
Drug: aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aripiprazole once-monthly 400mg
Trial: 23890595
Drug: aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: aripiprazole once-monthly (any dose)
Trial: 18047523
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg subcutaneously at week 0, then 40 mg every other week)
Trial: 18047523
Drug: Methotrexate (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (7.5 mg orally, increased as needed to 25 mg weekly)
Trial: 10848924
Drug: Pranlukast (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (225 mg orally twice daily for 4 weeks)
Trial: 10848924
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral administration for 4 weeks)
Trial: 8229102
Drug: Self-administered Quality-of-Life
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered Quality-of-Life after Myocardial Infarction (QLMI) questionnaire
Trial: 31777212
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/d) plus NSAID
Trial: 29893296
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine (5mg/kg/day) and topical terbinafine 1% applied twice daily for 4 weeks
Trial: 27515978
Drug: Guselkumab IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab IV (0.03-10 mg/kg)
Trial: 27515978
Drug: Guselkumab SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab SC (10-300 mg)
Trial: 27515978
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC (10, 30, 100, 300 mg)
Trial: 23281755
Drug: Chickens slaughtered
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chickens slaughtered at 2000 g
Trial: 23281755
Drug: Chickens slaughtered
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chickens slaughtered at 1500 g
Trial: 18390635
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 6 weeks
Trial: 16199251
Drug: Cefdinir (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir (once daily n = 569 or twice daily n = 1086) for 5 or 10 days
Trial: 16199251
Drug: Penicillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (4 times daily n = 1096) for 10 days
Trial: 12451319
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 or 20 mg/d)
Trial: 7476741
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of plain water two and half hours before surgery (Group 1)
Trial: 28836341
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy (OD)
Trial: 25499095
Drug: Caltrate 600
RxNorm normalized name: Caltrate 600 + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caltrate 600 mg elemental calcium; 125 IU vitamin D3, 1 tablet/day
Trial: 25499095
Drug: Caltrate 600
RxNorm normalized name: Caltrate 600 + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caltrate 600 mg elemental calcium; 125 IU vitamin D3, 2 tablets/day
Trial: 22416402
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution and 10% glucose solution (1:1 ratio)
Trial: 22416402
Drug: Sterofundin-G-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterofundin-G-5
Trial: 22416402
Drug: Remaksol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remaksol (800 ml/day)
Trial: 15196263
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of p336‐351 linked to cholera toxin B subunit (CTB), 3 times weekly, followed by gradual withdrawal of immunosuppressive drugs.
Trial: 15196263
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of p336‐351 linked to cholera toxin B subunit (CTB)
Trial: 11476424
Drug: Eccentric overload
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric overload training (12-week treatment protocol)
Trial: 3171265
Drug: Medical vagotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical vagotomy (0.5 mg of atropine and 50 mg of hexamethonium bromide, injected three times at two hour intervals intramuscularly)
Trial: 21601833
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg once a day)
Trial: 1687129
Drug: Formoterol (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (with inhaled steroids reintroduced)
Trial: 15876899
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release 300 mg/d
Trial: 27324341
Drug: Probiotic SYNBIO(®)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic SYNBIO(®) vaginal suppositories (Lactobacillus rhamnosus IMC 501(®) and Lactobacillus paracasei IMC 502(®)) administered daily for 7 days
Trial: 27324341
Drug: Probiotic SYNBIO(®)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic SYNBIO(®) vaginal suppositories
Trial: 24804879
Drug: Adrenocorticotropin hormone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropin hormone, epinephrine, and norepinephrine
Trial: 18367110
Drug: Cytoreductive nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive nephrectomy followed by interferon treatment
Trial: 8993854
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor antagonists (AT1 antagonists)
Trial: 8993854
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor antagonists (AT1 antagonists) with diuretic
Trial: 4033401
Drug: Dehydration (D)
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydration (D) with 40 mg of furosemide
Trial: 20508478
Drug: PHiD‐CV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV and MMRV vaccine
Trial: 20508478
Drug: DTPa‐HBV‐IPV/Hib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa‐HBV‐IPV/Hib and MMRV vaccines
Trial: 20508478
Drug: PHiD‐CV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV and DTPa‐HBV‐IPV/Hib vaccine
Trial: 15315997
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 IU) daily
Trial: 9296325
Drug: Pranlukast (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (300 mg) administered in the evening after a high fat meal
Trial: 9296325
Drug: Pranlukast (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (300 mg) administered in the morning after a high fat meal
Trial: 8191447
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of chloramphenicol eyedrops (0.5% eye drops, one drop hourly/every two hours for three days, thereafter every 4‐6 hours)
Trial: 8191447
Drug: Simplified dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified dosage of chloramphenicol eyedrops (four times a day)
Trial: 3075473
Drug: Euro‐Collins' solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euro‐Collins' solution (ECS; n = 9)
Trial: 3075473
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (RS; n = 9)
Trial: 22617860
Drug: Modafinil 255
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 255 mg daily
Trial: 22617860
Drug: Modafinil 340
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 340 mg daily
Trial: 22617860
Drug: Modafinil 425
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 425 mg daily
Trial: 22617860
Drug: Modafinil 510
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 510 mg daily
Trial: 22015077
Drug: Elvitegravir 150
RxNorm normalized name: elvitegravir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvitegravir 150 mg once daily
Trial: 16305290
Drug: Bitter-orange dried-fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter-orange dried-fruit extract (450 mg standardized to 27 mg of m- or p-synephrine)
Trial: 7534217
Drug: Atropine 10
RxNorm normalized name: Isopto Atropine 10 MG/ML Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 10 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 12)
Trial: 7534217
Drug: Atropine 20
RxNorm normalized name: Minims Homatropine 20 MG/ML Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 20 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 13)
Trial: 7534217
Drug: Vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg.kg‐1 (n = 11)
Trial: 913121
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg indomethacin daily
Trial: 30768161
Drug: 14 day
RxNorm normalized name: Ponvory 14 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day high-dose dual therapy (esomeprazole 40 mg three times daily and amoxicillin 750 mg four times daily for 14 days)
Trial: 30768161
Drug: 7 day
RxNorm normalized name: ZonaCort 7 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day non-bismuth quadruple therapy (esomeprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days)
Trial: 30768161
Drug: 14 day
RxNorm normalized name: Ponvory 14 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day high-dose dual therapy
Trial: 30768161
Drug: 7 day
RxNorm normalized name: ZonaCort 7 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day non-bismuth quadruple therapy
Trial: 25462663
Drug: Stimulant Craving
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant Craving Questionnaire (STCQ) for methamphetamine users
Trial: 25462663
Drug: Stimulant Craving
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant Craving Questionnaire (STCQ) for cocaine users
Trial: 21856349
Drug: HPV co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV co-administered with HepB
Trial: 8167653
Drug: Postexercise glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postexercise glucose ingestion (100 g glucose polymer drink)
Trial: 8167653
Drug: Postexercise glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postexercise glucose ingestion with potassium chloride (3 g KCl)
Trial: 2850604
Drug: s.c. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. injection of 8 micrograms alsactide
Trial: 2850604
Drug: s.c. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. injection of 10 micrograms alsactide
Trial: 2850604
Drug: s.c. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. injection of 20 micrograms alsactide
Trial: 2850604
Drug: i.v. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. injection of 2 micrograms alsactide
Trial: 2850604
Drug: i.v. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. injection of 4 micrograms alsactide
Trial: 2850604
Drug: i.v. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. injection of 8 micrograms alsactide
Trial: 19335435
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment applied twice daily for 8 weeks
Trial: 3052188
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation of Rhinalar (less propylene glycol)
Trial: 3052188
Drug: Original formulation
RxNorm normalized name: Zegerid (Original Formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original formulation of Rhinalar
Trial: 28656612
Drug: Caloric vestibular
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric vestibular stimulation (CVS) device (TNM™), 3-month treatment
Trial: 24257722
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g whey protein
Trial: 25979566
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g whey protein
Trial: 25979566
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g whey protein
Trial: 25979566
Drug: All conditions
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All conditions (20, 40, 60, 80 g whey protein)
Trial: 23052408
Drug: Sirolimus administered
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus administered simultaneously with tacrolimus
Trial: 23052408
Drug: Sirolimus administered
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus administered staggered after tacrolimus
Trial: 23052408
Drug: Tacrolimus administered
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus administered simultaneously with sirolimus
Trial: 23052408
Drug: Tacrolimus administered
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus administered staggered before sirolimus
Trial: 19222510
Drug: Tonabersat 20
RxNorm normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonabersat 20 mg daily for 2 weeks and 40 mg daily for a further 10 weeks
Trial: 12846595
Drug: Subcutaneous melagatran
RxNorm normalized name: melagatran
DrugBank: Melagatran (DB13616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous melagatran (3mg)
Trial: 12846595
Drug: Oral ximelagatran
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ximelagatran (24mg)
Trial: 10958095
Drug: Metoclopramide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.3 mg x kg(‐1))
Trial: 10958095
Drug: Dimenhydrinate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (1 mg x kg(‐1))
Trial: 10958095
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dimenhydrinate and metoclopramide
Trial: 8836333
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (local nasal immunotherapy with birch-alder allergens in powder form)
Trial: 4072649
Drug: Meticillin 1
RxNorm normalized name: methicillin
DrugBank: Meticillin (DB01603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meticillin 1 g X 4 intravenously on the day of operation
Trial: 23902481
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² administered once a week for 4 weeks)
Trial: 21816030
Drug: RTS, S/AS01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS, S/AS01 malaria vaccine
Trial: 19394194
Drug: Direct Treatment
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Treatment Model (DT)
Trial: 19394194
Drug: Collaborative-Consultation Treatment
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collaborative-Consultation Treatment Model (CC)
Trial: 19394194
Drug: Combined Treatment
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Treatment Model (CT)
Trial: 16928222
Drug: PBAT (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBAT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., amoxicillin‐clavulanate 1000 mg b.i.d., and tetracycline 500 mg q.i.d.)
Trial: 16928222
Drug: PBMT (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.)
Trial: 15173146
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g monthly)
Trial: 11340690
Drug: Intranasal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal triamcinolone acetonide 220 micrograms/day for six months
Trial: 11340690
Drug: Oral cetirizine
RxNorm normalized name: cetirizine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cetirizine 10 mg/day
Trial: 11340690
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate 400 micrograms/day
Trial: 8076759
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment (8.4-336 megaunits)
Trial: 28848330
Drug: Yogurt supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt supplemented with Lactobacillus paracasei N1115, 300 mL/d for 12 weeks
Trial: 25187210
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg intranasal scopolamine gel (INSCOP)
Trial: 25187210
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg intranasal scopolamine gel (INSCOP)
Trial: 25187210
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intranasal scopolamine gel (INSCOP)
Trial: 19359109
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone treatment
Trial: 8123410
Drug: i.v. clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. clonidine 30 micrograms diluted in saline to a total volume of 5 ml, repeated every 5 min up to a maximum dose of 90 micrograms
Trial: 8123410
Drug: saline 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 5 ml (placebo solution), repeated every 5 min up to a maximum of three boluses
Trial: 8123410
Drug: saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline (placebo) after initial clonidine treatment
Trial: 31039153
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of linezolid
Trial: 31039153
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of linezolid
Trial: 31039153
Drug: Long-term linezolid
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term linezolid treatment
Trial: 29016675
Drug: Team sport
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team sport group ingesting a drink high in protein (18 g) immediately and 3 h after each training session (TS-HP, n = 13)
Trial: 29016675
Drug: Team sport
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team sport group ingesting an isocaloric drink with low protein content (3 g; TS-LP, n = 18)
Trial: 25569128
Drug: Cerebral NIRS
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral NIRS monitoring with a dedicated treatment guideline during the first 72 hours of life
Trial: 23686030
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment for 5 weeks
Trial: 19799601
Drug: Glycerol 855
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol 855 mg/kg
Trial: 19799601
Drug: Glycerol 1710
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol 1710 mg/kg
Trial: 19799601
Drug: Control (healthy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (healthy individuals) 1710 mg/kg
Trial: 2891534
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg temazepam administered at 0900 h (day-time)
Trial: 2891534
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg temazepam administered at 2200 h (night-time)